Product Image

Contributor Information

  • Name Anne Lykkesfeldt
  • Institute Danish Cancer Society, Denmark
  • Primary citation Lykkesfeldt et al. 1995. Int J Cancer. 61(4):529-534. PMID: 7759159.

Tool Details

  • Tool name: MCF7/182R-7 Cell Line
  • Alternate names: MCF-7/182R-7; 182R-7
  • Tool type: Cell Lines
  • Tool sub-type: Continuous
  • Parental cell line: MCF7 S0.5
  • Organism: Human
  • Tissue: Breast
  • Gender: Female
  • Cancer type: Breast cancer
  • Disease: Cancer
  • Model: Tumour line
  • Application: Investigation of molecular changes
  • Description: The MCF7/182R-7 cell line is a breast cancer cell line resistant to fulvestrant (Faslodex).

    The MCF7/182R-7 cell line is a human breast cancer cell line established from a clone of MCF7/S0.5 cells surviving long term growth with the pure steroidal antiestrogen ICI 182,780 (fulvestrant) in 100 nM concentration. The cellular classification is epithelial, and their shape is polygonal.

    MCF7/182R-7 cells express oestrogen receptor alpha and do not express progesterone receptor. The passage number of MCF7/182R-7 is 427, 430.

    Treatment with the steroidal antioestrogen fulvestrant has proven effective upon progression on tamoxifen therapy and is now approved for second-line treatment after tamoxifen or aromatase inhibitors. As for tamoxifen treatment of advanced breast cancer, resistance will inevitably occur also for fulvestrant. Clarification of the molecular changes associated with the resistant growth is needed to find targeted treatments to resistant tumour cells and treatments that can inhibit or delay the emergence of resistance.
  • Research area: Cancer; Drug development
  • Production details: The MCF7/182R-7 cell line has been established from a clone of MCF7/S0.5 cells surviving long term growth with the pure steroidal antiestrogen ICI 182,780 in 100 nM concentration, Lykkesfeldt et al (1995). The MCF7/182R-7 cells can be maintained continuously in growth medium with 100 nM fulvestrant.
  • Cellosaurus ID: CVCL_1D41
  • Additional notes: Upon withdrawal of fulvestrant, the cells express ER alpha, although at a reduced level. The MCF7/182R-7 cells do not express progesterone receptor. The MCF7/182R-7 cells express increased level of EGFR, phosphorylated EGFR and phosphorylated ErbB3 and reduced level of ErbB4 compared to the parental MCF7/S0.5 cells.

  • For Research Use Only

Target Details

  • Target: Oestrogen receptor

Application Details

  • Application: Investigation of molecular changes
  • Application notes: Upon withdrawal of fulvestrant, the cells express ER alpha, although at a reduced level. The MCF7/182R-7 cells do not express progesterone receptor. The MCF7/182R-7 cells express increased level of EGFR, phosphorylated EGFR and phosphorylated ErbB3 and reduced level of ErbB4 compared to the parental MCF7/S0.5 cells. Passage 427(AL3419), 430 (AL3779)

Handling

  • Format: Frozen
  • Passage number: Passage 427(AL3419), 430 (AL3779)
  • Growth medium: Phenol red free DMEM/F12 (1:1) supplemented with 1% FCS, Glutamax 2.5 mM and 6 ng/ml insulin. Supplemented with 100nM fulvestrant to maintain resistance.
  • Temperature: 37° C
  • Atmosphere: 5% CO2
  • Shipping conditions: Dry ice

Documentation

Related Tools

Product Image

K38 Keratinocyte Cell Line

#151682
Product Image

C75 Colorectal adenocarcinoma Cell Line

#151758
Product Image

PC346C 24 [ABI B] CRPC Cell line

#161834

References

  • •  Thrane et al. 2014. Oncogene. 34(32):4199-4210. PMID: 25362855.
  • •  Frogne et al. 2009. Breast Cancer Res Treat. 114(2):263-275. PMID: 18409071.
  • •  Frankel et al. 2007. Breast Cancer Res Treat. 104(2):165-179. PMID: 17061041.
  • •  Frogne et al. 2005. Endocr Relat Cancer. 12(3):599-614. PMID: 16172194.
  • •  Christensen et al. 2004. Breast Cancer Res Treat. 85(1):53-63. PMID: 15039597.
  • •  Larsen et al. 1997. Int J Cancer. 72(6):1129-1136. PMID: 9378550.
  • •  Lykkesfeldt et al. 1995. Int J Cancer. 61(4):529-534. PMID: 7759159.